According to Mordor Intelligence, the global industrial hemp market is projected to grow from USD 3.57 billion in 2026, ...

Youth cannabis use between ages 9 and 17 years is associated with slower cognitive development during a time of key brain ...

Today Kazmira Therapeutics announced the official launch of 1Cannabis, an online medical cannabis education platform. This ...

Rachel Carr Shreves and Crystal Howard of Spencer Fane discuss the proposed federal rescheduling of cannabis to Schedule III ...

A Neuropsychopharmacology Circumspectives article argues that cannabidiol has genuine therapeutic potential, especially in ...

A new UC San Diego study strengthens the growing body of evidence that marijuana use impacts adolescent brain development.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present six abstracts, including one oral presentation, at the 2026 American Academy of Neurology (AAN) Annual Meeting, ...

Jazz Pharmaceuticals (JAZZ) remains in focus on Tuesday morning after President Donald Trump demanded that the DOJ proceed quickly to reclassify cannabis as a Schedule III drug. The company spent $7.2 ...

According to 2025 data from the National Conference of State Legislatures (NCSL), medical marijuana is legal in 40 states and ...

Many American leagues no longer test for THC, but that doesn't mean the sports world has reached a consensus on cannabis.